SCHEMBL4289960

SCHEMBL4289960

CN(C)c1ccc(N=Nc2ccc(N3C(=O)C=CC3=O)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 11/20 0.52
FAAH O00519 4/20 0.52
MAPK1 P28482 5/20 0.52
ALDH1A1 P00352 4/20 0.52
TSHR P16473 3/20 0.52
TDP1 Q9NUW8 3/20 0.52
HSD17B10 Q99714 2/20 0.52
NPC1 O15118 5/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
RAB9A P51151 4/20 0.49
MAPT P10636 3/20 0.49
POLB P06746 2/20 0.49
KDM4E B2RXH2 2/20 0.49
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
TP53 P04637 1/20 0.46
HIF1A Q16665 1/20 0.46
PSMD14 O00487 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458382 1.00 MGLL (0.52) MGLLFAAHMAPK1ALDH1A1TSHR
SCHEMBL27650867 0.95 MGLL (0.50) MGLLFAAHMAPK1ALDH1A1TSHR
SCHEMBL3759716 0.89 MGLL (0.65) MGLLFAAHMAPK1ALDH1A1TSHR
SCHEMBL11410714 0.85 MGLL (0.71) MGLLFAAHMAPK1ALDH1A1TDP1
SCHEMBL5150580 0.79 MGLL (0.52) MGLLFAAHMAPK1ALDH1A1TDP1
SCHEMBL8467655 0.79 HSP90AA1 (0.64) MGLLFAAHMAPK1ALDH1A1TDP1
SCHEMBL4289963 0.79 NPC1 (0.54) MGLLFAAHMAPK1ALDH1A1TSHR
SCHEMBL2696242 0.78 MGLL (0.65) MGLLFAAHMAPK1ALDH1A1TDP1
SCHEMBL2696243 0.78 MGLL (0.65) MGLLFAAHMAPK1ALDH1A1TDP1
SCHEMBL3665727 0.77 MGLL (0.65) MGLLFAAHMAPK1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577563-B2 Methods for multiplexing recombinase polymerase amplification ABBOTT DIAGNOSTICS SCARBOROUGH, INC. (US) 2026-03-17 US disclosed
EP-4615966-A1 METHODS AND COMPOSITIONS FOR PROCESSING AND AMPLIFICATION OF NUCLEIC ACIDS Biomeme, Inc. (US) 2025-09-17 EP disclosed
EP-4612326-A1 COMPOSITIONS AND METHODS FOR THE DETECTION AND ANALYSIS OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2) AND VARICELLA ZOSTER VIRUS (VZV) Abbott Molecular Inc. (US) 2025-09-10 EP disclosed
EP-4282961-B1 COMPOSITIONS FOR THE DETECTION AND ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS ABBOTT MOLECULAR INC (US) 2025-08-20 EP disclosed
US-20250161948-A1 PORTABLE DEVICES AND METHODS FOR ANALYZING SAMPLES Biomeme, Inc. 2025-05-22 US disclosed
US-20250121369-A1 METHODS AND SYSTEMS FOR AUTOMATED SAMPLE PROCESSING Biomeme, Inc. 2025-04-17 US disclosed
US-20250093342-A1 ANALYZING CELL SAMPLES FIRST-CITIZENS BANK & TRUST COMPANY 2025-03-20 US disclosed
US-20250085276-A1 COMPOSITIONS AND METHODS FOR SERIAL TARGET DETECTION FIRST-CITIZENS BANK & TRUST COMPANY 2025-03-13 US disclosed
WO-2025049452-A1 DEVICES AND METHODS FOR PROCESSING SAMPLES Biomeme, Inc. (US) 2025-03-06 WO disclosed
US-20240426815-A1 SERIAL DETECTION OF MULTIPLE TARGETS FIRST-CITIZENS BANK & TRUST COMPANY 2024-12-26 US disclosed
US-8273705-B2 Conversion of apoptotic proteins THE BURNHAM INSTITUTE (US) 2012-09-25 US disclosed
US-20090215984-A1 CONVERSION OF APOPTOTIC PROTEINS THE BURNHAM INSTITUTE (US) 2009-08-27 US disclosed
US-7491700-B2 Conversion of apoptotic proteins THE BURNHAM INSTITUTE (US) 2009-02-17 US disclosed
US-20070117753-A1 CONVERSION OF APOPTOTIC PROTEINS THE BURNHAM INSTITUTE (US) 2007-05-24 US disclosed
US-7176277-B2 Conversion of apoptotic proteins THE BURNHAM INSTITUTE (US) 2007-02-13 US disclosed
US-20060193864-A1 Conversion of apoptotic proteins NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2006-08-31 US disclosed
US-6994979-B2 Conversion of apoptotic proteins THE BURNHAM INSTITUTE (US) 2006-02-07 US disclosed
US-20040220097-A1 Conversion of apoptotic proteins NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-11-04 US disclosed
WO-2004052920-A9 CONVERSION OF APOPTOTIC PROTEINS BURNHAM INST (US) 2004-08-19 WO disclosed
WO-2004052920-A2 CONVERSION OF APOPTOTIC PROTEINS THE BURNHAM INSTITUTE (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577563-B2 Methods for multiplexing recombinase polymerase amplification POLL, POLM, DNMT3A MGLL 3366/4885FAAH 4163/4885MAPK1 4154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.